• Centrient is a pioneer in fighting the risk of AMR and has worked to shape the independent standard to be used for the industry
• Centrient’s Santa Perpetua site was among the first to pilot the programme

Centrient Pharmaceuticals is proud to announce it received independent certification for meeting international standards for Minimized Risk of Antimicrobial Resistance (AMR) for its site in Santa Perpetua, Spain.

As a leader in the campaign against AMR, and a founding member of the AMR Industry Alliance (IA), Centrient has been working to shape the standards used for this certification for other pharmaceutical companies and has been one of the first antibiotic manufacturers to spearhead the pilot program with the British Standards Institute (BSI), the business improvement and standards company, and the AMR IA.

Piloted in early 2023, this certification scheme was developed to ensure an independent and international industry standard for the responsible manufacturing of antibiotics and to address environmental waste concerns in antibiotic production.

“Our team worked diligently to obtain this certification,” said Centrient  Chief Human Resources, Communications and ESG Officer, Jean-Luc Giraud. “As Centrient has ensured all its sites are PNEC compliant, this certification further attests to our efforts in prioritizing the sustainable production of our medicines, improving the lives of patients worldwide. We thank our team in Spain for taking part in this initiative.”    

According to the World Health Organization, AMR remains a top ten global health threat and is expected to get worse unless action is taken. This certification thus confirms our role as a leader in combatting AMR through responsible manufacturing of antibiotics in the global supply chain and minimizing the risk of antibiotic waste emissions in the environment.

BSI, a business improvement and standards company, launched the BSI Kitemark for minimized risk of antimicrobial resistance certification programme to ensure that companies protect the efficacy of antibiotics for future generations. The certification follows the Antibiotic Manufacturing Standard, established by the AMR IA, to allow for independent third-party verification that waste streams containing antibiotic APIs and drug products are appropriately controlled during manufacturing by pharmaceutical companies.

Centrient announced earlier this year that it received a gold rating from EcoVadis, a trusted provider of business sustainability ratings.